key: cord-0748874-nntkk4pf
authors: Toombs, Jessica M; Van den Abbeele, Koenraad; Democratis, Jane; Merricks, Rhona; Mandal, Amit K J; Missouris, Constantinos G
title: COVID‐19 in 3 people living with HIV in the United Kingdom
date: 2020-06-15
journal: J Med Virol
DOI: 10.1002/jmv.26178
sha: 027d13265df7477966a139f831e4d10d88fd4b21
doc_id: 748874
cord_uid: nntkk4pf

We would like to report the clinical characteristics of 3 people living with HIV (PLWH) in the United Kingdom within the context of coronavirus disease 2019 (COVID‐19). Our institution serves a population of 500,000 with a prevalence of HIV at 0.34%. At of the time of writing, 5(th) June 2020, only 3 PLWH tested positive for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) on nasopharyngeal swab specimen using Real‐Time Reverse Transcriptase‐Polymerase Chain Reaction (RT‐PCR) have required admission to hospital. This article is protected by copyright. All rights reserved.

Funding: The authors received no specific funding for this work.

Disclosures: No potential conflict of interest was reported by the authors.

We would like to report the clinical characteristics of 3 people living with HIV (PLWH) in the United Kingdom within the context of coronavirus disease 2019 . Our institution serves a population of 500,000 with a prevalence of HIV at 0.34%. At of the time of writing, 5 th June 2020, only 3 PLWH tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on nasopharyngeal swab specimen using Real-Time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) have required admission to hospital. These account for 0.43% of total This article is protected by copyright. All rights reserved.

COVID 19 admissions to our hospital where the overall mortality rate is currently 27%. There are scarce data available on PLWH and COVID-19 and although our case series is small, it may be relevant.

We treated 3 Black patients: 2 male and 1 female. 1 male patient required intubation soon after admission and died in the intensive care unit (ITU) while the other 2 patients required continuous positive airway pressure (CPAP) and were subsequently discharged in a good condition. Preadmission CD4 counts varied from 50/mm 3 to 890/mm 3 and each patient was prescribed different antiretroviral therapy (ART) regimens, none of which contained lopinavir-ritonavir. Two of the regimens contained tenofovir which has theoretical antiviral activity [1, 2] . They all remained on preadmission ART regimens in accordance with guidance from the British HIV Association [3] .

Patient 1 was a 62-year-old polymorbid Nigerian male with risk factors for poor outcomes in COVID-19. He had received a renal transplant, was immunocompromised from tacrolimus and mycophenolate treatment, and also had type 2 diabetes (T2DM) and hypertension. He was intubated and ventilated on ITU and died from multi-organ failure precipitated by COVID-19 pneumonitis. A high mortality rate has been associated with transplant patients infected with COVID-19 who require hospitalisation [4] and this, alongside other comorbidities, all of which are cited as poor prognostic markers, likely contributed to death rather than HIV status. Patient 2, a 46-year-old Jamaican male with glucose-6-phosphate dehydrogenase (G6PD) deficiency, had been ART naïve until 5 days prior to admission after he had been lost to follow up since diagnosis in 2013. With a CD4 count of 50/mm 3 and a viral load >1 million/ml, in the setting of COVID-19 infection, This article is protected by copyright. All rights reserved.

it was felt likely he had added PCP and this was later supported by positive serum beta-D-glucan. He was treated with atovaquone in view of G6PD deficiency and had a good outcome. Patient 3, a 57 year old Zimbabwean female with a history of stroke, T2DM, hypertension and obesity, was a nurse in an older persons care home with confirmed COVID-19 infections at the time of admission. She also was covered for added bacterial infection and was discharged in a good condition.

We suggest that HIV alone does not result in amplified risk of infection or adverse outcomes in COVID-19 infection when compared to the general population. This is supported by case series from both Germany and America, where no excess morbidity or mortality was found among HIV patients [5, 6] . Furthermore, Karmen-Tuohy et al compared a cohort of HIV-positive patients to a matched non-HIV cohort and concluded that HIV coinfection did not significantly impact presentation, hospital course or long term outcomes [7] . Patient 2 of our series, who in retrospect fulfilled AIDS defining criteria, did not suffer a more severe disease course -the assumption being that even these patients are not necessarily at heightened risk. As HIV is seen in an increasingly aging population, these patients may have comorbidities which independently augment the risk of adverse outcomes, and therefore, any conclusions drawn should be cautious. We postulate that HIV patients may even be somewhat protected if established on ART [8] . All of the above hypotheses need to be validated by further research with greater patient numbers.

Demographics, clinical characteristics, treatment, and outcomes of 3 patients with HIV and COVID-19 are demonstrated.

This article is protected by copyright. All rights reserved.

Demographics 

Recovery from COVID-19 in two patients with coexisted HIV infection

Triphosphates of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase

BHIVA guidance for the management of adults with HIV on antiretroviral treatment (ART) during the coronavirus pandemic

COVID-19 in kidney transplant recipients

COVID -19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection

A Case Series of Five People Living with HIV Hospitalized with COVID-19 in

Outcomes among HIV-positive patients hospitalized with COVID-19

SARS-CoV-2 and HIV